Bovine mastitis, an inflammation of the mammary gland due to pathogen invasion, continues to be a main concern in the global dairy industry. Mastitis is the main reason dairy cows are administered antibiotics, and the antibiotics utilized for mastitis treatment and prevention tend to be classified as medically important. In an effort to develop antibiotic alternatives and decrease the amount of antibiotics used for mastitis therapy, Elanco desires a novel solution to prevent, treat, or control mastitis in cattle.
*** Webinar *** An online webinar presented by Elanco and InnoCentive concerning Elanco's Grand Challenge Program will be held on October 20, 2016 at 10:30 AM (US Eastern Time). The webinar will include a question and answer session. Register in advance here: https://innocentive.webex.com/innocentive/j.php?RGID=re71ea91971dce8a5bd40cbb6d0d0b74c.
After registering, you will receive a confirmation email with a link to join the webinar. A recording will be attached to this Challenge for those who are unable to attend.
This Theoretical Challenge requires only a written proposal.
Bovine mastitis is a costly disease of the dairy industry especially due to losses from early culling of lactating cows, decreased milk production, and inferior milk quality. Infection of the mammary gland by opportunistic bacteria causes mastitis and the most contagious pathogens have evolved to produce virulence factors that promote chronic survival. Treatment of mastitis by antibiotics has the potential not only for creating antibiotic resistant organisms, but also antibiotic contamination of milk for human consumption. To decrease antibiotic usage for mastitis therapy, Elanco desires a novel solution to prevent, treat, or control mastitis in cattle.
This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker.
To receive an award, the Solvers will have to transfer to the Seeker their exclusive Intellectual Property (IP) rights to the solution.
Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on October 23, 2016.
Late submissions will not be considered.
ABOUT THE SEEKER
Elanco provides comprehensive products and knowledge services to improve animal health and food-animal production in more than 70 countries around the world. We value innovation, both in scientific research and daily operations, and strive to cultivate a collaborative work environment for nearly 7,000 employees worldwide. Together with our customers, we are committed to raising awareness about global food security, and celebrating and supporting the human-animal bond. Elanco has committed to an 8-step Antibiotic Stewardship Plan that ensures the responsible use of antibiotics, reduces shared-class antibiotic use, and replaces antibiotics with alternatives. Founded in 1954, Elanco is a division of Eli Lilly and Company. Our worldwide headquarters and research facilities are located in Greenfield, Indiana. Visit us at Elanco.com and EnoughMovement.com.
What is a Theoretical IP Transfer Challenge?
An InnoCentive Theoretical Challenge builds upon an idea but is not yet a proof of concept. A solution to a Theoretical Challenge will solidify the Solver's concept with detailed descriptions, specifications and requirements necessary to bringing a good idea closer to becoming an actual product or service.
This Challenge is a Theoretical-IP Transfer Challenge, meaning that Solvers must relinquish all rights to the Intellectual Property (IP) for which they are awarded. By contrast, Theoretical-Licensing means that the Seeker is requesting non-exclusive rights to use the winning solution. For these forms of a Theoretical Challenge, Solvers that do not win retain the rights to their solution after the evaluation period is complete. The Seeker retains no rights to any IP not awarded.